BACKGROUND: With the introduction of prolonged prophylaxis with valganciclovir in
cytomegalovirus (CMV) donor/recipient serodiscordance (D+/R−) patients, concerns about a …

Prolonging cytomegalovirus (CMV) prophylaxis in CMV seronegative recipients of a kidney
from CMV seropositive donor (D+/R–) may reduce the incidence of late infections. We …

Late-onset cytomegalovirus (CMV) disease remains common in CMV serology naïve kidney
transplant patients of CMV serology positive organs (D+/R–) despite the use of antiviral …

Background Cytomegalovirus (CMV) remains the leading viral cause of disease following
orthotopic liver transplantation (OLT) despite the availability of antiviral agents for …

The clinical patterns and predictors of cytomegalovirus (CMV) disease in kidney and/or
pancreas transplant patients on ganciclovir (1.0 g po tid) or valganciclovir (450 mg po qd) …

Background Cytomegalovirus (CMV) can cause severe infections in transplanted patients.
To prevent CMV infection, most liver centers use prophylaxis for CMV-seronegative …

Background: Valganciclovir prophylaxis is reportedly associated with a low incidence of
ganciclovir‐resistant cytomegalovirus (CMV). We assessed the incidence, clinical features …

Background. The role of valganciclovir in the prevention of cytomegalovirus (CMV) disease
in high-risk seropositive transplant patients is not known. Methods. We prospectively …

Background. We assessed the impact of a preemptive strategy after discontinuation of
antiviral prophylaxis in the prevention of late-onset cytomegalovirus (CMV) disease in a …

Background. Despite advances in antiviral therapies, cytomegalovirus (CMV) remains the
leading opportunistic infection in the transplant population. Valganciclovir (VGC), the l‐valyl …